The FDA announced today that it tentatively plans to hold a meeting of the General and Plastic Surgery Devices Panel, March 25-26. The meeting will take place at the FDA’s headquarters in Silver Spring, Md.
The meeting will discuss a range of topics concerning benefit-risk profiles of breast implants, according to the FDA.
Breast implants are considered implantable medical devices. They are implanted under the breast tissue or under the chest muscle for augmentation or reconstructive surgery. They can also be used in revision surgeries.
Two types of breast implants are currently approved for sale in the U.S.. These include saline-filled and silicone gel-filled. Both types have a silicone outer shell and vary in size, thickness, shell surface texture and shape.